Aging, COPD, and other risk factors do not explain the increased prevalence of pulmonary Mycobacterium avium complex in Ontario

Chest

Volumn 141, Issue 1, 2012, Pages 190-197

  Al Houqani, Mohammed ^a   Jamieson, Frances ^b,c   Mehta, Mauli ^d   Chedore, Pamela ^b   May, Kevin ^b   Marras, Theodore K ^d  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE; AGED; AGING; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIUM ISOLATION; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; ORGAN TRANSPLANTATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; SEX DIFFERENCE;

EID: 84855465416     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0089     Document Type: Article

References (41)

1. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax. 2007;62(8):661-666. (Pubitemid 47235003)
2. Marras TK, Mehta M, Al Houqani M, et al. Isolation prevalence of pulmonary nontuberculous mycobacteria, Ontario 2008. Am J Respir Crit Care Med. 2010;18(1):19-24.
3. Hanna BA, Ebrahimzadeh A, Elliott LB, et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. J Clin Microbiol. 1999;37(3):748-752. (Pubitemid 29091296)
4. Griffith DE, Aksamit T, Brown-Elliott BA, et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases [published correction appears in Am J Respir Crit Care. 2007;175(7):744-745]. Am J Respir Crit Care Med. 2007;175(4):367-416. (Pubitemid 46271561)
5. Marras TK, Mehta M, Chedore P, May K, Al Houqani M, Jamieson F. Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung. 2010;188(4):289-299.
6. Andréjak C, Thomsen VO, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181(5):514-521.
7. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated healthcare delivery systems. Am J Respir Crit Care Med.2010;182(7):970-976.
8. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features; an emerging public health disease. Am J Respir Crit Care Med. 2010;182(7):977-982.
9. Remis RS, Liu J. Epidemiology of HIV infection in Ontario: update to 2009. University of Toronto Web site. http://www.phs.utoronto.ca/ohemu/doc/ HIV%20epi%20Ontario%202009%20Final.pdf. Accessed January 2010.
10. Trillium Gift of Life Network. Transplant 10-year history. Trillium Gift of Life Network Web site. http://www.giftoflife.on.ca/en/statistics/ transplant10yrhistory.htm. Accessed January 15, 2010.
11. Bombardier C, Paterson J, Zagorski B, et al. Use of biologic response modifying drugs by Ontario rheumatology [abstract]. J Rheumatol. 2009;36(11):2590.
12. Statistics-Canada. Canadian Community Health Survey (CCHS). Ottawa, Ontario: University of Toronto Data Library Service; 2010.
13. Statistics Canada: Canada's national statistical agency. Statistics Canada Web site. http://www.statcan.gc.ca. Accessed January 15, 2010.
14. Bates JH. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clin ical characteristics. XX. A report of the Veterans Administration-armed forces cooperative study on the chemotherapy of tuberculosis. Am Rev Respir Dis. 1967;96(6):1151-1157.
15. Robinson BL, Grzybowski S, Bowmer EJ, McDiarmid J, Whittaker EI, Tanner K. Atypical mycobacterial disease in British Columbia, 1960-1967. Can Med Assoc J. 1969;101(1):17-24.
16. Yeager H Jr, Raleigh JW. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis. 1973;108(3):547-552.
17. Rosenzweig DY. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest. 1979;75(2):115-119. (Pubitemid 9128100)
18. Engbaek HC, Vergmann B, Bentzon MW. Lung disease caused by Mycobacterium avium/Mycobacterium intracellulare.An analysis of Danish patients during the period 1962-1976. Eur J Respir Dis. 1981;62(2):72-83. (Pubitemid 11153199)
19. Connolly MJ, Magee JG, Hendrick DJ, Jenkins PA. Mycobacterium malmoense in the north-east of England. Tubercle. 1985;66(3):211-217. (Pubitemid 16150081)
20. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989;321(13):863-868. (Pubitemid 19238618)
21. Debrunner M, Salfinger M, Brändli O, von Graevenitz A. Epidemiology and clinical significance of nontuberculous mycobacteria in patients negative for human immunodeficiency virus in Switzerland. Clin Infect Dis. 1992;15(2):330-345.
22. Choudhri S, Manfreda J, Wolfe J, Parker S, Long R. Clinical significance of nontuberculous mycobacteria isolates in a Canadian tertiary care center. Clin Infect Dis. 1995;21(1):128-133.
23. Donnabella V, Salazar-Schicchi J, Bonk S, Hanna B, Rom WN. Increasing incidence of Mycobacterium xenopi at Bellevue hospital: an emerging pathogen or a product of improved laboratory methods? Chest. 2000;118(5):1365-1370.
24. van Ingen J, Boeree MJ, de Lange WC, et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis. 2008;14(3):385-389. (Pubitemid 351451384)
25. Murray MP, Laurenson IF, Hill AT. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Clin Infect Dis.2008;47(2):222-224. (Pubitemid 351920624)
26. Gerogianni I, Papala M, Kostikas K, Petinaki E, Gourgoulianis KI. Epidemiology and clinical significance of mycobacterial respi ratory infections in central Greece. Int J Tuberc Lung Dis. 2008;12(7):807-812. (Pubitemid 351976713)
27. van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64(6):502-506.
28. Marusić A, Katalinić-Janković V, Popović-Grle S, et al. Mycobacterium xenopi pulmonary disease - epidemiology and clinical features in non-immunocompromised patients. J Infect. 2009;58(2):108-112.
29. van Ingen J, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis. 2010;14(9):1176-1180.
30. Gershon AS, Wang C, Wilton AS, Raut R, To T. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med. 2010;170(6):560-565.
31. Bodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis. 2008;14(3):390-396. (Pubitemid 351451385)
32. Maugein J, Dailloux M, Carbonnelle B, Vincent V, Grosset J; French Mycobacteria Study Group. Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. Eur Respir J. 2005;26(6):1092-1096. (Pubitemid 41829942)
33. Good RC, Snider DE Jr. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis. 1982;146(6):829-833. (Pubitemid 13211885)
34. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis. 2009;49(12):e124-e129.
35. Al Houqani M, Jamieson F, Chedore P, Mehta M, May K, Marras TK. Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario in 2007. Can Respir J.2011;18(1):19-24.
36. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med. 2007;176(3):306-313. (Pubitemid 47195882)
37. von Reyn CF, Green PA, McCormick D, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis. 1994;19(1):15-20.
38. Brown RS, Hussain M. The Walkerton tragedy - issues for water quality monitoring. Analyst (Lond). 2003;128(4):320-322. (Pubitemid 36520709)
39. Salvadori MI, Sontrop JM, Garg AX, Moist LM, Suri RS, Clark WF. Factors that led to the Walkerton tragedy. Kidney Int Suppl. 2009;75(112):S33-S34.
40. Trnka L, Danková D, Svandová E. Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuber Lung Dis. 1994;75(5):348-352. (Pubitemid 24336531)
41. Romanus V, Hallander HO, Wåhlén P, Olinder-Nielsen AM, Magnusson PH, Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis. 1995;76(4):300-310.